Industry Experience of the Concentration-QTc Relationship in Phase 1 Studies. Corina Dota, AstraZeneca
|
|
- George Oliver
- 5 years ago
- Views:
Transcription
1 Industry Experience of the Concentration-QTc Relationship in Phase 1 Studies Corina Dota, AstraZeneca CSRC-2 th February 2012
2 ICH E Alternative Strategies to Assess QT/QTc Interval Effects Alternatives to the use of the thorough QT/QTc study are under active investigation. Examples include evaluating the relationship between concentration and QT/QTc effects or more intensively evaluating ECGs, based on data collected during early phase clinical studies Analysis of Relationship Between Drug Exposure and QT/QTc Interval Changes Establishing the relationship of drug concentrations to changes in QT/QTc interval may provide additional information to assist the planning and interpretation of studies assessing cardiac repolarization. This area is under active investigation. 2 CSRC 2 Feb 2012
3 QT/QTc Evaluation in AstraZeneca: integrated risk-assessment In silico In vitro In vivo SAD MAD TQT Late-stage monitoring 3 CSRC 2 Feb 2012
4 Current strategy SAD/MAD Criteria for inclusion/exclusion, stopping and time table for frequent coordinated decg and PK measurements are set according to pre-clinical data. High quality decgs and time synchronized decg/pk measurements enable exploration of effects on decg parameters (PR interval, QRS duration, QT interval, RR) in relation to ascending drug concentrations in SAD/MAD studies. 4 CSRC 2 Feb 2012 TQT A negative thorough QT/QTc study is one in which the upper bound of the 95% one-sided confidence interval for the largest-time matched mean effect of the drug on the QTc interval excludes 10 ms. The methods for decg collection, analysis and choice of primary endpoint QTc may depend on drug properties, e.g. increase in heart rate.
5 Current strategy High quality decgs in SAD/MAD/TQT - same high quality and precision methodology for recording and analysis of 12 lead digital ECG recordings in SAD/MAD/TQT - EClysis - Analysis performed by a few, skilled, blinded analysts at a centralised ECG core laboratory - Known precision and variability of the methods and of the analysts 5 CSRC 2 Feb 2012
6 Current strategy: Overview of example of timepoints for decg in a SAD study The decg time points are adjusted to and reflect the PK time points, the decg (10 replicates of 10-sec recordings per 5 min period) are recorded immediately before draw of blood tests, BP measurements or other PD tests. 6 CSRC 2 Feb 2012
7 Questions: - How often do Phase I results fail to detect a signal when there is a positive TQT? - If there is a positive slope identified from Concentration- Response analysis (CR) of Phase I data, how different is that from the slope estimated from TQT data? CSRC-2 th February 2012
8 Case Studies Example 1 Pre-clinical evidence of QT/QTc prolongation risk of AZDxxx confirmed in SAD study herg data Dog telemetry data Predicted free C max at efficacious dose SAD QT/QTc prolongation in SAD compound stopped 8 CSRC 2 Feb 2012
9 Case Studies Example 1 Clinical verification of QT/QTc prolongation QT/QTc prolongation in SAD 9 CSRC 2 Feb 2012
10 Case Studies Example 2: Summary of QT/QTc evaluation in phase 1 studies for AZDyyy before the TQT study No clinically concerning cardiac issues Thorough review of digital ECG and 12 lead ECG data had been performed in phase 1 studies no issues identified No individual or mean changes above the categorical values of concern PK/PD modelling of all available decg data (single and multiple dose) suggested low likelihood of effect in TQT reaching the ICH E14 threshold 10 CSRC 2 Feb 2012
11 Case Studies Example 2 TQT study: 2 dose levels drug, active control and placebo Primary analysis demonstrates a negative TQT outcome at both doses of drug. All upper bounds of the 2-sided 90% CI are below 10 ms. (n= 59) Effect of therapeutic and supratherapeutic dose of AZDyyy on ΔΔQTcF 11 CSRC 2 Feb 2012
12 Case Studies Example 3 PK/PD in phase 1 and Negative TQT No statistically significant QTcF --- AZDzzz concentration relationship for a phase I study with 6D+2P subjects for each of 900 mg and 1260 mg doses No statistically significant QTcF --- AZDzzz concentration relationship for the TQT study for 900 mg dose (supratherapeutic dose) 12 CSRC 2 Feb 2012
13 Summary Preliminary analysis suggests that: Concentration-Response analysis of phase 1 data can detect small effects of compounds on QT/QTc, despite relatively small number of subjects, smaller number of placebo subjects, and absence of positve control for assay sensitivity Absence of effect and non-significant Concentration- QT/QTc relationship from phase 1 studies may indicate a negative TQT study No available in-house data allowing opportunity to evaluate predictivity (and magnitude of effect) of a positive TQT based on QT/QTc- Concentration modeling of phase 1 data 13 CSRC 2 Feb 2012
14 Participation in External Collaborations and Initiatives HESI- Proarrhythmia Working Group- main goal to study the predictive value of non-clinical studies for the outcome of the TQT study, with a sub-group compiling early clinical study data to compare with the TQT study outcome TI Pharma PK/PD modeling platform: University- Industry consortium Other initiatives in the industry 14 CSRC 2 Feb 2012
15 Current In-house Initiatives - Ongoing project: AZ Cardiovascular Exploration (ACE)- preclinical/clinical cardiovascular data exploration platform to enable evaluation of novel approaches to analysis and interpretation of CV data, including translational methodologies - Recently started Predictive Safety project to build a platform where predictive utility (quantitative assessment) of available data from early phase studies for the results of TQTs can be assessed and enhanced designs for SAD/MAD will be evaluated using Modeling and Simulation 15 CSRC 2 Feb 2012
16 Question: Can an integrated approach (preclinical and early clinical data) using a Modeling and Simulation approach (PK/PD and statistical) appropriately characterize the QT/QTc and therefore replace the TQT study for many or most compounds in development? A concerted effort is needed to collaboratively work on this important topic: - Retrospective data - Prospective project(s) 16 CSRC 2 Feb 2012
17 Thank you!
Definitive QTc Assessment in Early Phase Trials: Expectations from FDA s Interdisciplinary Review Team
Definitive QTc Assessment in Early Phase Trials: Expectations from FDA s Interdisciplinary Review Team Jiang Liu, Ph.D. Scientific Lead for QT-IRT Division of Pharmacometrics Office of Clinical Pharmacology
More informationQT Assessment: The new paradigm, but now what? Joy Olbertz PharmD, PhD Senior Director, Cardiovascular Safety Services
QT Assessment: The new paradigm, but now what? Joy Olbertz PharmD, PhD Senior Director, Cardiovascular Safety Services The Evolution of ICH E14 Points to Consider Joint Health Canada/FDA Concept Paper
More informationData Quality in Small QTc Studies. Marek Malik, London
Data Quality in Small QTc Studies Marek Malik, London marek.malik@btinternet.com marek.malik@imperial.ac.uk Data Quality in Small QTc Studies DISCLAIMER Views and opinions presented are only my own Data
More informationIQ-CSRC PROSPECTIVE QTc STUDY Study Design and Choice of Drugs
IQ-CSRC PROSPECTIVE QTc STUDY Study Design and Choice of Drugs Nenad Sarapa, MD IQ-CSRC meeting, Silver Spring, MD 12 December 2014 Background SAD studies can reliably assess QTc prolongation if proper
More informationTQT studies - this is the end!
TQT studies - this is the end! Borje Darpo MD, PhD Associate Professor of Cardiology Chief Scientific Officer icardiac Technologies Yes as the only way to confidently exclude that a new drug has a clinically
More informationPreparing for Changing Cardiac Safety Regulations. Joy Olbertz, PharmD, PhD
Preparing for Changing Cardiac Safety Regulations Joy Olbertz, PharmD, PhD Questions? Do I still have to assess proarrhythmic potential of my compound in a Thorough QT (TQT) study? If I have a TQT to conduct,
More informationIQ-CSRC Prospective Study - Background and Objectives
IQ-CSRC Prospective Study - Background and Objectives December 12, 2014 Borje Darpo MD, PhD icardiac Technologies Co-chair SoC, CSRC Objectives of the IQ-CSRC Prospective Study The objective of the initiative
More informationIQ-CSRC PROSPECTIVE STUDY RESULTS. Steve Riley, PharmD, PhD IQ-CSRC meeting December 12, 2014
IQ-CSRC PROSPECTIVE STUDY RESULTS Steve Riley, PharmD, PhD IQ-CSRC meeting December 12, 2014 IQ-CSRC prospective study - Design 20 male and female healthy subjects 3 treatment periods 9 subjects were to
More informationInterpreting Adult Human Thorough QT Studies: Are They Relevant to Pediatric Safety?
Interpreting Adult Human Thorough QT Studies: Are They Relevant to Pediatric Safety? Hao Zhu, Ph.D. Scientific Lead, QT-IRT, FDA (Dec 10, 2010) Disclaimer: The views expressed in this talk are those of
More informationBreakout #4 Phase 1 ECG:
Breakout #4 Phase 1 ECG: Potential Role of ECG under CiPA HESI CSRC CiPA Meeting Washington, DC - May 22, 2018 Jose Vicente, PhD Christine Garnett, PharmD Division of Cardiovascular and Renal Products
More informationThe Maximum Mean Difference
The Maximum Mean Difference Statistical Problems in Assessing Cardiac Safety Georg Ferber, Novartis Pharma AG, Basel ROeS Seminar Bern, 10-13 Sep 2007 Overview QT prolongation some background The Thorough
More informationDesign and Analysis of QT/QTc Studies Conceptional and Methodical Considerations Based on Experience
Design and Analysis of QT/QTc Studies Conceptional and Methodical Considerations Based on Experience Dr. Manfred Wargenau, Institute, Düsseldorf OVERVIEW Clinical background The ICH E14 guideline / review
More informationThe QT Interval Safety Endpoint for DR- TB trials. Kelly Dooley & Gary Maartens (Disclaimer: I know very little cardiac electrophysiology)
The QT Interval Safety Endpoint for DR- TB trials Kelly Dooley & Gary Maartens (Disclaimer: I know very little cardiac electrophysiology) The ECG tracing Physiology of a cardiac myocyte Flow of ions (Na
More informationGuidance for Industry
Reprinted from FDA s website by Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R1) U.S. Department
More informationIQ/CSRC Study Waveform Sharing Program
IQ/CSRC Study Waveform Sharing Program Presentation for CSRC members August 26, 2015 Borje Darpo, icardiac Cindy Green, DCRI Georg Ferber, Independent Brian Smith, icardiac Jean-Philippe Couderc, THEW
More informationConcentration QTc Assessment in Early Phase Trials
Concentration QTc Assessment in Early Phase Trials Fang Liu*, Li Fan, Kuenhi Tsai, Devan V. Mehrotra ASA Biopharmaceutical Section Regulatory Industry Statistics Workshop September 14, 2018 Washington,
More informationIMPLEMENTATION OF NOVEL ECG BIOMARKERS
IMPLEMENTATION OF NOVEL ECG BIOMARKERS CSRC CiPA meeting May 21, 2018 Washington DC Borje Darpo, MD, PhD, FESC Chief Scientific Officer, Cardiac Safety, ERT 1 Disclosures I work as a consultant for ERT,
More informationCardiovascular Safety Assessments in Early Phase Oncology Clinical Trials
CSRC Think Tank: Detection, Assessment and Risk Mitigation of Cardiac Safety Signals in Oncology Drug Development Cardiovascular Safety Assessments in Early Phase Oncology Clinical Trials Boaz Mendzelevski,
More informationEMA EFPIA workshop Breakout Session 2 Assessing the Probability of Drug-Induced QTc-Interval Prolongation During Early Clinical Drug Development
EMA EFPIA workshop Breakout Session 2 Assessing the Probability of Drug-Induced QTc-Interval Prolongation During Early Clinical Drug Development Oscar Della Pasqua GSK Background Drugs that prolong QT
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationFDA's Analysis and Interpretation of the IQ/CSRC Clinical Study
FDA's Analysis and Interpretation of the IQ/CSRC Clinical Study Jiang Liu Scientific Lead of QT-IRT Division of Pharmacometrics OCP/OTS/CDER/FDA Disclaimer: My remarks today do not necessarily reflect
More informationNew ECG Biomarkers and their Potential Role in CiPA: Results and Implications
New ECG Biomarkers and their Potential Role in CiPA: Results and Implications HESI CSRC CiPA Meeting Washington, DC - May 21, 2018 Jose Vicente, PhD for the ECG Biomarker Working Group Division of Cardiovascular
More informationCSRC White Papers. An update Dec. 2010
CSRC White Papers An update Dec. 2010 Ignacio Rodriguez, MD Clinical Safety Risk Management Roche ignacio.rodriguez.ir1@roche.com CSRC White Papers Position papers usually cover challenging areas of cardiovascular
More informationEXPOSURE RESPONSE ANALYSIS TO EVALUATE A DRUG'S EFFECT ON ECG PARAMETERS
EXPOSURE RESPONSE ANALYSIS TO EVALUATE A DRUG'S EFFECT ON ECG PARAMETERS Christine Garnett, PharmD DCRP, FDA April 6, 2016 CSRC/FDA Workshop: The Proarrhythmic Assessment of New Chemical Entities Disclosures
More informationQT Studies for Biologics QT assessment in phase I Workshop 2
QT Studies for Biologics QT assessment in phase I Workshop 2 Philippe L Hostis Joint Conference of European Human Pharmacological Societies and 20th Anniversary of AGAH Berlin, 31st March 2011 QT assessment
More informationStudy Day 1 Study Days 2 to 9 Sequence 1 Placebo for moxifloxacin Study Days 2 to 8: placebo for pazopanib (placebopaz) 800 mg;
The study listed may include approved non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRecent insights from the FDA QT-IRT on concentration-qtc analysis and requirements for TQT study ( waiver ) substitution
Recent insights from the FDA QT-IRT on concentration-qtc analysis and requirements for TQT study ( waiver ) substitution Dhananjay D. Marathe, Ph.D. QT-IRT Lead, Office of Clinical Pharmacology US FDA
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe pharmacological positive control can be replaced by a meal.
The pharmacological positive control can be replaced by a meal. Wednesday, April 6th, 2016 CSRC/FDA Workshop: The Pro-arrhythmic Assessment of New Chemical Entities ACC Heart House Washington, D.C. Jorg
More informationICH guideline E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic
25 January 2016 EMA/CHMP/ICH/310133/2008 Committee for Human Medicinal Products ICH guideline E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic
More informationEvaluation of the Effect of Dapagliflozin on Cardiac Repolarization: a Thorough QT/QTc Study
Diabetes Ther (2011) 2(3):123-132. DOI 10.1007/s13300-011-0003-2 ORIGINAL RESEARCH Evaluation of the Effect of Dapagliflozin on Cardiac Repolarization: a Thorough QT/QTc Study Glenn F. Carlson Conrad K.
More informationIn Vitro Assessment to Replace the Clinical TQT Study: The Comprehensive In Vitro ProArrhythmia Assay (CiPA) Initiative
In Vitro Assessment to Replace the Clinical TQT Study: The Comprehensive In Vitro ProArrhythmia Assay (CiPA) Initiative Gary Gintant, AbbVie for the Comprehensive in Vitro ProArrhythmia Assay Group Hot
More informationQT prolongation and drug-drug interactions. Filip Josephson M.D., Ph.D Clinical Assessor Swedish Medical Products Agency
QT prolongation and drug-drug interactions Filip Josephson M.D., Ph.D Clinical Assessor Swedish Medical Products Agency Disposition Introduction to QT prolongation Three relevant DDI scenarios Concluding
More informationQT QT Study Design and Statistical Evaluation of QT Prolongation Introduction and QT Interval Correction
QT QT Study Design and Statistical Evaluation of QT Prolongation Introduction and QT Interval Correction Yasushi Orihashi Clinical Data and Biostatistics Department, Daiichi Sankyo Co., Ltd. email: orihashi.yasushi.c2@daiichisankyo.co.jp
More informationSuccesses and Evolving Challenges Posed by the Comprehensive In Vitro Proarrhythmia (CiPA) Initiative
Successes and Evolving Challenges Posed by the Comprehensive In Vitro Proarrhythmia (CiPA) Initiative Gary Gintant Dept. Integrative Pharmacology Integrated Sciences and Technology AbbVie For the CiPA
More informationbeyond AMPS LLC, New York, USA Hopital Lariboisiere, Paris, France
The Holter bin approach and beyond Fabio Badilini, PhD AMPS LLC, New York, USA Pierre Maison-Blanche, MD Hopital Lariboisiere, Paris, France 1 Outlines Background of quantitative digital ECG The rate RR
More informationAlex Dmitrienko (Eli Lilly and Company), Chair of Distance Training, Biopharmaceutical Section of ASA
Spring 2008 series Introduction Alex Dmitrienko (Eli Lilly and Company), Chair of Distance Training, Biopharmaceutical Section of ASA Assessment of QTc prolongation in clinical drug development Alex Dmitrienko
More informationICH E14 THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON-ANTIARRHYTHMIC DRUGS.
European Medicines Agency London, 25 May 2005 CHMP/ICH/2/04 ICH E14 THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON-ANTIARRHYTHMIC DRUGS ICH Step 4 NOTE FOR
More informationEstimation of the Power of the Food Effect on QTc to Show Assay Sensitivity
Drug Development Estimation of the Power of the Food Effect on QTc to Show Assay Sensitivity The Journal of Clinical Pharmacology 2018, 58(1) 81 88 C 2017, The Authors. The Journal of Clinical Pharmacology
More informationAdaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient
Adaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient Michelle L. Combs, PhD Vice President, Clinical Pharmacology Sciences New Drug And Biologics
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationModeling and Simulation Approaches for Cardiovascular Function and Their Role in Safety Assessment
Citation: CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 175 188; VC 2015 ASCPT All rights reserved doi:10.1002/psp4.18 REVIEW Modeling and Simulation Approaches for Cardiovascular Function and Their Role
More informationAlbiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study
Diabetes Ther (2014) 5:141 153 DOI 10.1007/s13300-014-0055-1 ORIGINAL RESEARCH Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study Borje Darpo Meijian Zhou Jessica Matthews
More informationGuidance for Industry
Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs U.S. Department of Health and Human Services Food and Drug Administration
More informationEvaluating the Use of Linear Mixed-Effect Models for Inference of the Concentration-QTc Slope Estimate as a Surrogate for a Biological QTc Model
Citation: CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 1 9; doi:10.1002/psp4.14 VC 2015 ASCPT All rights reserved ORIGINAL ARTICLE Evaluating the Use of Linear Mixed-Effect Models for Inference of the
More informationEvaluation of the Cardiac Safety of Long- Acting Endectocide Moxidectin in a Randomized Concentration- QT Study
Citation: Clin Transl Sci (2018) 11, 582 589; doi:10.1111/cts.12583 ARTICLE Evaluation of the Cardiac Safety of Long- Acting Endectocide Moxidectin in a Randomized Concentration- QT Study Sally A. Kinrade
More informationPacing in Drug Testing
ISHNE International Society for Holter and Noninvasive Electrocardiology 1 st Worldwide Internet Symposium on Drug- Induced QT Prolongation October 1-15, 1 15, 2007 Pacing in Drug Testing I Savelieva,
More informationFor Discussion Purposes Only
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 Step 1 Draft 2 (July 17, 2003) Draft 3 (November 12, 2003), Draft 4 (June 10, 2004)
More informationCan the Thorough QT Study Be Replaced? Norman Stockbridge Division of Cardiovascular and Renal Products FDA/CDER
Can the Thorough QT Study Be Replaced? Norman Stockbridge Division of Cardiovascular and Renal Products FDA/CDER Can the TQT study be replaced? Yes. Thank you. Any questions? Four genre of replacement
More informationThe Use of a Multi-modal Pain Test Battery in Early Phase Clinical Drug Development
The Use of a Multi-modal Pain Test Battery in Early Phase Clinical Drug Development The Annual Pain & Migraine Therapeutics Summit 2017, San Diego G.J. Groeneveld, MD, PhD Research Director Neurology &
More informationConcentration-QTc analysis to obviate the need for a dedicated QTc study in cancer patients: ixazomib, an oral proteasome inhibitor, as a case study
Concentration-QTc analysis to obviate the need for a dedicated QTc study in cancer patients: ixazomib, an oral proteasome inhibitor, as a case study Neeraj Gupta, Ph.D. Outline Concentration-QTc analysis
More informationFood can serve as a non pharmacological control in thorough cardiac safety studies
Food can serve as a non pharmacological control in thorough cardiac safety studies Jorg Taubel MD FFPM Washington 14 th April 2011 Disclaimer The views and opinions expressed in the following PowerPoint
More informationResults From the IQ-CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase
Results From the IQ-CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase B Darpo 1,2 *, C Benson 3, C Dota 4 *, G Ferber 5, C Garnett 6 *, CL
More informationDrug Discoveries & Therapeutics. 2010; 4(1):44-53.
44 Drug Discoveries & Therapeutics. 21; 4(1):44-3. Original Article Exposure-response modeling and clinical trial simulation of the effect of tolterodine on QT intervals in healthy volunteers Kevin R.
More informationECG-PS ECG SIGNAL MEASUREMENT MODULE. Operation Manual. March 2005
ECG-PS ECG SIGNAL MEASUREMENT MODULE Operation Manual March 2005 2555 Collins Avenue, Suite C-5 - Miami Beach FL - 33140 - U.S.A. Phone #: (305) 534-5905 Fax: (305) 534-8222 e-mail: info@galix-gbi.com
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationRecent Developments in the Analysis of QT Interval Data
Recent Developments in the Analysis of QT Interval Data Robb Muirhead Statistical Research & Consulting Center Pfizer Global Statistics Graybill Conference VII Colorado State University June 12, 2008 1
More informationPharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches.
Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches. Lloyd Stevens PhD Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationEffect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a Phase I Randomized Study in Healthy Subjects
Citation: Clin Transl Sci (2017) 10, 208 216; C 2017 ASCPT. All rights reserved doi:10.1111/cts.12452 ARTICLE Effect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationCiPA, Pre-clinical Testing. Derek Leishman PhD DSP & ICH S7B
CiPA, Pre-clinical Testing Derek Leishman PhD DSP & ICH S7B Outline Introduction Scenarios Conclusion Expressing an opinion What is not covered? Analysis/critique of the components too little time to try
More informationDevelopment and Use of Quantitative Adverse Outcome Pathways: Lessons Learned from Application to Cardiotoxicity
Development and Use of Quantitative Adverse Outcome Pathways: Lessons Learned from Application to Cardiotoxicity Chemicals Concentration 0.1 µm 1 µm 10 µm 100 µm Weihsueh A. Chiu, PhD Department of Veterinary
More informationThe Opportunity: c-ibs and pain relief with confidence YKP10811
The Opportunity: c-ibs and pain relief with confidence YKP10811 1 TABLE OF CONTENTS Profile Summary Clinical Data Mode of Action Pharmacologic Profile Safety and Toxicity Profile ADME Overview vs. Competitors
More informationWorkshop # 3 : Application of Bayesian Statistics in early development studies
Workshop # 3 : Application of Bayesian Statistics in early development studies Francois Vandenhende, ClinBAY Patricia Sanwald Ducray, Roche Joint Conference of European Human Pharmacological Societies
More informationIs there an "Adequate" Heart Rate Correction for QT?
Is there an "Adequate" Heart Rate Correction for QT? R&D Information Technology, GGOIB Biometry&Biosignals Abbott GmbH&Co.KG D-67061 Ludwigshafen/Rhein International Biometric Society, German Region QT/QTc
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationComparison of Electrocardiographic Biomarkers for Differentiating. Drug-induced Single vs. Multiple Cardiac Ion Channel Block
Article Type: Article Comparison of Electrocardiographic Biomarkers for Differentiating Drug-induced Single vs. Multiple Cardiac Ion Channel Block Marina Brockway 1, Jay W. Mason 2,3, Brian P. Brockway
More informationMEA assays using human ipsc-derived cardiomyocytes; challenges and opportunities
MEA assays using human ipsc-derived cardiomyocytes; challenges and opportunities Event Presenter Date EMA Workshop 2017 Tessa de Korte, MSc 2017, October 5 Page 1 Ncardia at a glance Foundation Ncardia
More informationInter-study variability of preclinical in vivo safety studies and translational exposure QTc relationships a PKPD meta-analysis
BJP British Journal of Pharmacology DOI:1.1111/bph.13218 www.brjpharmacol.org RESEARCH PAPER Inter-study variability of preclinical in vivo safety studies and translational exposure QTc relationships a
More informationImplications of methodological differences in digital electrocardiogram interval measurement B
Journal of Electrocardiology 39 (2006) S152 S156 www.elsevier.com/locate/jelectrocard Implications of methodological differences in digital electrocardiogram interval measurement B Fabio Badilini, PhD,
More informationCan non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium
BJP British Journal of Pharmacology RESEARCH PAPER British Journal of Pharmacology (2018) 175 606 617 606 Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results
More informationPK-PD modelling to support go/no go decisions for a novel gp120 inhibitor
PK-PD modelling to support go/no go decisions for a novel gp120 inhibitor Phylinda LS Chan Pharmacometrics, Pfizer, UK EMA-EFPIA Modelling and Simulation Workshop BOS1 Pharmacometrics Global Clinical Pharmacology
More informationAbsolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches.
Absolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches. Dr Lloyd Stevens Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationSummary ID#4668 Clinical Study Summary: Study B4Z-MC-LYAQ
CT Registry ID#4668 Page 1 Summary ID#4668 Clinical Study Summary: Study B4Z-MC-LYAQ Date summary approved by Lilly: 09 August 2005 Title of Study: Safety and Efficacy of Atomoxetine or Atomoxetine Plus
More informationJoint Annual meeting 2005 AGAH-Club Phase I
Joint Annual meeting 2005 AGAH-Club Phase I Early Drug Development Scientific and Regulatory challenges Strasbourg, March 17-18, 2005 Early drug development Scientific and Regulatory challenges QTc: Predictability,
More informationComparison of Two Highly Automated ECG Algorithms for Detection of Drug-Induced Cardiac Ion Channel Block
Comparison of Two Highly Automated ECG Algorithms for Detection of Drug-Induced Cardiac Ion Channel Block Marina Brockway 1, Anthony A. Fossa 2 and Jay W. Mason 3,4 US Food and Drug Administration (FDA)
More informationCognitive Research Corporation
Cognitive Research Corporation Contract Research Organization offering specialized expertise to fit the unique needs of each client Bobbie Theodore clinicaltrials@alliancesites.com An Alliance of Quality
More informationIntravenous Conivaptan: Effects on the QTc Interval and Other Electrocardiographic Parameters in Healthy Volunteers
Advances in Therapy Volume 24 No. 2 March/April 2007 Intravenous Conivaptan: Effects on the QTc Interval and Other Electrocardiographic Parameters in Healthy Volunteers Kenneth C. Lasseter, MD Stacy C.
More informationLenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QTc Intervals in the Thorough QTc Study Conducted in Healthy Men
Basic & Clinical Pharmacology & Toxicology, 2013, 113, 179 186 Doi: 10.1111/bcpt.12081 Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QTc Intervals in the Thorough QTc Study Conducted
More informationPKPD-Modelling of QT Prolongation Following Deliberate Self-Poisonings with Citalopram
PKPD-Modelling of QT Prolongation Following Deliberate Self-Poisonings with Citalopram Lena Friberg 1, Geoffrey Isbister 2, Peter Hackett 3 and Stephen Duffull 1 1 School of Pharmacy, University of Queensland,
More informationSelective Cardiac Myosin Activators in Heart Failure
Selective Cardiac Myosin Activators in Heart Failure John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationIs a Maximal Tolerated Dose in Human useful for drug development?
Is a Maximal Tolerated Dose in Human useful for drug development? How to define an acceptable highest dose to be tested? EuFeMED, London Pre-conference Workshop 17-May-2017 Eric Legangneux Philippe Grosjean
More informationSYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005
Drug product: SYMBICORT pmdi 160/4.5 μg Drug substance(s): Budesonide/formoterol Study code: SD-039-0728 Edition No.: FINAL Date: 27 February 2006 SYNOPSIS A 52-week, randomized, double-blind, single-dummy,
More informationAddressing Evolving CHMP Guidance of Phase I Study Designs
Addressing Evolving CHMP Guidance of Phase I Study Designs BIA 10-2474 background Lutz Müller Project Leader in Pharmaceutical Science Roche Innovation Center Basel Context: Modern Ph I Studies Are Generally
More informationJ. Täubel 1,2,G.Ferber 3, S. Fernandes 1, E. Santamaría 4, and I. Izquierdo 4. Original Manuscript
Original Manuscript Cardiac Safety of Rupatadine in a Single-Ascending-Dose and Multiple-Ascending-Dose Study in Healthy Japanese Subjects, Using Intensive Electrocardiogram Assessments Comparison With
More informationDisclosures (2013 to the present)
What level and types of CV safety data acquisition should be considered to sufficiently characterize a drug s benefit/risk assessment by the end of Phase 3 development? Cardiac Safety Research Consortium
More informationEarly drug development: assessment of proarrhythmic risk and cardiovascular safety
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016 VOL. 9, NO. 12, 1611 1618 http://dx.doi.org/10.1080/17512433.2016.1245142 REVIEW Early drug development: assessment of proarrhythmic risk and cardiovascular
More informationSummary ID# Clinical Study Summary: Study B4Z-JE-LYBC
CT Registry ID# 5285 Page 1 Summary ID# 5285 Clinical Study Summary: Study B4Z-JE-LYBC A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Hydrochloride
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationExposure-response in the presence of confounding
Exposure-response in the presence of confounding Jonathan L. French, ScD Metrum Research Group LLC May 3, 2016 c 2016 Metrum Research Group LLC TICTS, Durham, NC, 2016 May 3, 2016 1 / 24 Outline 1 Introduction
More informationLack of an Effect of Standard and Supratherapeutic Doses of Linezolid on QTc Interval Prolongation
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2011, p. 4302 4307 Vol. 55, No. 9 0066-4804/11/$12.00 doi:10.1128/aac.01723-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Lack
More informationPreclinical Perspectives of QT Outlook from ICH Guidelines
Biometry in Early Clinical Research QT/QTc Interval Workshop in Heidelberg, November 17-19, 2005 Preclinical Perspectives of QT Outlook from ICH Guidelines Gerd Bode, M.D.,Ph.D. Frelance Consultant, e-mail
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/19939 holds various files of this Leiden University dissertation. Author: Chain, Anne S.Y. Title: Mind the gap : predicting cardiovascular risk during drug
More informationThe QT interval as it relates to the safety of non-cardiac drugs
European Heart Journal Supplements (2007) 9 (Supplement G), G3 G8 doi:10.1093/eurheartj/sum047 The QT interval as it relates to the safety of non-cardiac drugs Peter R. Kowey 1 * and Marek Malik 2,3 1
More informationImplications of Individual QT/RR Profiles Part 1: Inaccuracies and Problems of Population Specific QT/Heart Rate Corrections
Drug Safety https://doi.org/10.1007/s40264-018-0736-1 ORIGINAL RESEARCH ARTICLE Implications of Individual QT/RR Profiles Part 1: Inaccuracies and Problems of Population Specific QT/Heart Rate Corrections
More informationStudy Centers: This study was conducted in 2 centers in Italy.
Title of Trial: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationElectrocardiographic Markers Associated with Sotalol-induced Torsades de Pointes
Electrocardiographic Markers Associated with Sotalol-induced Torsades de Pointes Based on Data from the Telemetric and Holter ECG Warehouse (THEW) Initiative Jean-PhiIippe Couderc, PhD Center for Quantitative
More informationAssessing proarrhythmic potential of drugs when optimal studies are infeasible
Assessing proarrhythmic potential of drugs when optimal studies are infeasible Edwin P. Rock, MD, PhD, a John Finkle, MD, a Howard J. Fingert, MD, b Brian P. Booth, PhD, c Christine E. Garnett, PharmD,
More information